Pfizer ‘integrity’ deal will not hit PR

NEW YORK: The ‘corporate integrity agreement’ signed by Pfizer as part of a fraud case settlement will not affect its PR operations, the US drugs giant said last week.

Pfizer agreed to pay $430m in fines, and to sign an agreement allowing greater government monitoring of its marketing and staff training, as part of the plea agreement in a case that involved the marketing of drug Neurontin.

A component of the agreement dealt with staff who engage in ‘sales, marketing, or promotion of Pfizer products, or the provision of information about or services relating to Pfizer’s products’, according to the document.

But spokespeople are not covered by the agreement, said senior corporate comms director Mariann Caprino.

Pfizer said the improper activity occurred at Warner-Lambert’s Parke-Davis division between 1996 and 2000. Pfizer bought Warner-Lambert in 2000.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in